TARCEVA Side Effects

6902518-6 | Diarrhoea, Dyspnoea, Gout, Keratitis, Nervous System Disorder, Pyrexia, Respiratory Disorder
on Jul 15, 2010 Male patient from FRANCE , 66 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, dyspnoea, gout (What is gout?), keratitis, nervous system disorder, pyrexia, respiratory disorder. Tarceva dosage: (150 Mg,qd),oral. Patient was hospitalized.

6902506-X | Keratoconjunctivitis Sicca, Ulcerative Keratitis
Patient was taking Tarceva (View Usage). Patient had the following side effects: keratoconjunctivitis sicca, ulcerative keratitis on Jul 14, 2010 from SPAIN Additional patient health information: Female patient , 76 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized and became disabled.

6896373-0 | Acute Myocardial Infarction, Anaemia, Cardiac Failure Congestive, Gastrooesophageal Reflux Disease, Hypertension, Intracardiac Thrombus, Leukocytosis, Pericardial Effusion, Pericardial Haemorrhage
Adverse event was reported on Jul 20, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: Oral) . Location: UNITED STATES , 91 years of age, After Tarceva was administered, patient had the following side effects: acute myocardial infarction, anaemia, cardiac failure congestive, gastrooesophageal reflux disease, hypertension, intracardiac thrombus, leukocytosis, pericardial effusion, pericardial haemorrhage.

6887458-3 | Convulsion
on Jul 13, 2010 Male patient from COLOMBIA , 69 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.


6882878-5 | Disorientation, Malignant Neoplasm Progression
on Jul 12, 2010 Male patient from JAPAN , 82 years of age, weighting 106.3 lb, was treated with Tarceva (View Usage). Patient had the following side effects: disorientation, malignant neoplasm progression. Tarceva dosage: (100 Mg, Qd), Oral. During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), SERMION (NICERGOLINE) (View Sermion (nicergoline) Review and Sermion (nicergoline) Label ), URINORM (BENZBROMARONE) (View Urinorm (benzbromarone) Review and Urinorm (benzbromarone) Label ), NAUZELIN (DOMPERIDONE) (View Nauzelin (domperidone) Review and Nauzelin (domperidone) Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), ADALAT (NIFEDIINE) (View Adalat (nifediine) Review and Adalat (nifediine) Label ), MUCOSOLVAN (AMBROXOL HYDROCHLORIDE) (View Mucosolvan (ambroxol Hydrochloride) Review and Mucosolvan (ambroxol Hydrochloride) Label ), TIOTROPIUM BROMIDE (View Tiotropium Bromide Review and Tiotropium Bromide Label ).

6881382-8 | Loss Of Consciousness, Presyncope
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: loss of consciousness, presyncope on Jul 28, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 204.6 lb, . Tarceva dosage: 2800 Mg. During the same period patient was treated with GEMCITABINE HYDROCHLORIDE (6270 Mg) (View Gemcitabine Hydrochloride Review and Gemcitabine Hydrochloride Label ). Patient was hospitalized.

6874817-8 | Cholangitis, Decreased Appetite, Interstitial Lung Disease
Adverse event was reported on Jul 09, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with lung adenocarcinoma and. Location: JAPAN , 76 years of age, Patient experienced the following unwanted or unexpected effects: cholangitis, decreased appetite, interstitial lung disease. During the same period patient was treated with AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), COLDRIN (CLOFEDANOL HYDROCHLORIDE) (View Coldrin (clofedanol Hydrochloride) Review and Coldrin (clofedanol Hydrochloride) Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ).

6874815-4 | Cardiac Failure
on Jul 08, 2010 Male patient from CHINA , 71 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: cardiac failure. Tarceva dosage: (150 Mg), Oral.

6874750-1 | Haemorrhage, Rash
on Jul 09, 2010 Male patient from UNITED STATES , 42 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: haemorrhage, rash (What is rash?). Tarceva dosage: (100 Mg, Qd), Oral.

6874599-X | Asthenia, Cardiovascular Insufficiency, Rash, Respiratory Failure
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, cardiovascular insufficiency, rash (What is rash?), respiratory failure on Jul 07, 2010 from POLAND Additional patient health information: Female patient , 67 years of age, was diagnosed with pancreatic carcinoma and. Tarceva dosage: (100 Mg, Qd), Oral. During the same period patient was treated with GEMZAR (View Gemzar Review and Gemzar Label ).

6874516-2 | Decreased Appetite, Dehydration, Eastern Cooperative Oncology Group Performance Status, Fatigue, Nausea
Adverse event was reported on Jul 23, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 4800 Mg) . Location: UNITED STATES , weighting 103.2 lb, Patient had the following side effects: decreased appetite, dehydration, eastern cooperative oncology group performance status, fatigue, nausea (What is nausea?). Patient was hospitalized.

6874413-2 | Rash
on Jul 23, 2010 Male patient from UNITED STATES , 84 years of age, weighting 207.0 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: rash (What is rash?). Tarceva dosage: 150mg, Daily, Oral.

6866007-X | Asthenia, Decreased Appetite, Diarrhoea
on Jul 02, 2010 Male patient from FRANCE , 91 years of age, was diagnosed with metastatic bronchial carcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, decreased appetite, diarrhoea. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with DOXYCYCLINE (100 Mg, Qd, Oral) (View Doxycycline Review and Doxycycline Label ). Patient was hospitalized.

6865825-1 | Blood Albumin Decreased, Blood Creatinine Increased, C-reactive Protein Increased, Decreased Appetite, Dehydration, Diarrhoea, Malignant Neoplasm Progression, Non-small Cell Lung Cancer Metastatic, Platelet Count Decreased
Patient was taking Tarceva (View Usage). Patient had the following side effects: blood albumin decreased, blood creatinine increased, c-reactive protein increased, decreased appetite, dehydration, diarrhoea, malignant neoplasm progression, non-small cell lung cancer metastatic, platelet count decreased on Jul 05, 2010 from JAPAN Additional patient health information: Male patient , 70 years of age, weighting 84.22 lb, was diagnosed with non-small cell lung cancer and. Tarceva dosage: 150 Mg,qd,oral. During the same period patient was treated with FAMOTIDINE (View Famotidine Review and Famotidine Label ), LOXONIN (LOXOPROFEN SODIUM) (View Loxonin (loxoprofen Sodium) Review and Loxonin (loxoprofen Sodium) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), NIFEDIPINE (View Nifedipine Review and Nifedipine Label ).

6862985-3 | Bile Duct Obstruction, Dry Eye, Erythema, Folliculitis, Onychomycosis
Adverse event was reported on Jul 02, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: 150 Mg, Qd, Oral) was diagnosed with bronchial carcinoma and. Location: FRANCE , 59 years of age, After Tarceva was administered, patient had the following side effects: bile duct obstruction, dry eye, erythema, folliculitis, onychomycosis. During the same period patient was treated with XATRAL (ALFUZOSIN) (View Xatral (alfuzosin) Review and Xatral (alfuzosin) Label ), NICARDIPINE HCL (View Nicardipine Hcl Review and Nicardipine Hcl Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

6862976-2 | Effusion, Haemothorax, Pruritus, Rash
on Jul 02, 2010 Male patient from CYPRUS , 76 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: effusion, haemothorax, pruritus, rash (What is rash?). Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ). Patient was hospitalized.

6862519-3 | Dermatitis Acneiform, Disease Progression, Neutropenia, Pancreatic Carcinoma, Rash, Thrombocytopenia, Vomiting
on Jul 01, 2010 Female patient from POLAND , 31 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: dermatitis acneiform, disease progression, neutropenia, pancreatic carcinoma, rash (What is rash?), thrombocytopenia, vomiting. Tarceva dosage: (100 Mg, Qd), Oral. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ).

6862517-X | Dysaesthesia, Erythema
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: dysaesthesia, erythema on Jul 01, 2010 from GREECE Additional patient health information: Male patient , 52 years of age, was diagnosed with lung adenocarcinoma metastatic and. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6861481-7 | Chest Pain, Dyspnoea
Adverse event was reported on Jun 30, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 125 Mg, Qd, Oral) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 61 years of age, Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), dyspnoea. During the same period patient was treated with ALIMTA (View Alimta Review and Alimta Label ), AVASTIN (View Avastin Review and Avastin Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6856913-4 | Blood Bilirubin Increased, Decreased Appetite, Dehydration, Depressed Level Of Consciousness, Gastric Ulcer Haemorrhage, Hepatic Function Abnormal, Inflammation, Intracardiac Thrombus, Pneumonia
on Jun 29, 2010 Male patient from JAPAN , 75 years of age, was treated with Tarceva (View Usage). Patient had the following side effects: blood bilirubin increased, decreased appetite, dehydration, depressed level of consciousness, gastric ulcer haemorrhage, hepatic function abnormal, inflammation, intracardiac thrombus, pneumonia (What is pneumonia?). Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with TS 1 ((80 Mg, 2 D), Oral) (View Ts-1 Review and Ts-1 Label ), CHLORPROMAZINE HCL (View Chlorpromazine Hcl Review and Chlorpromazine Hcl Label ), MIYARI BACTERIA (MIYARI BACTERIA) (View Miyari Bacteria (miyari Bacteria) Review and Miyari Bacteria (miyari Bacteria) Label ), ROHYPNOL (FLUNITRAZEPAM) (View Rohypnol (flunitrazepam) Review and Rohypnol (flunitrazepam) Label ), LOXOPROFEN (LOXOPROFEN) (View Loxoprofen (loxoprofen) Review and Loxoprofen (loxoprofen) Label ), ANOXAN (AMOXAPINE) (View Anoxan (amoxapine) Review and Anoxan (amoxapine) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ). Patient was hospitalized.

6846961-2 | Balance Disorder, Coordination Abnormal, Intracranial Pressure Increased, Malignant Neoplasm Progression
on Jun 28, 2010 Female patient from BRAZIL , 48 years of age, was diagnosed with lung cancer metastatic and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: balance disorder, coordination abnormal, intracranial pressure increased, malignant neoplasm progression. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with CARBOXYMETHYLCELLULOSE SODIUM (CARMELLOSE SODIUM) (View Carboxymethylcellulose Sodium (carmellose Sodium) Review and Carboxymethylcellulose Sodium (carmellose Sodium) Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ), PHENOBARBITAL TAB (View Phenobarbital Tab Review and Phenobarbital Tab Label ), PRAVASTATIN (View Pravastatin Review and Pravastatin Label ). Patient was hospitalized.

6846960-0 | Burning Sensation, Erythema, Liver Injury, Malignant Neoplasm Progression, Metastases To Lung, Palmar-plantar Erythrodysaesthesia Syndrome, Paraesthesia
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: burning sensation, erythema, liver injury, malignant neoplasm progression, metastases to lung, palmar-plantar erythrodysaesthesia syndrome, paraesthesia on Jun 28, 2010 from JAPAN Additional patient health information: Female patient , 68 years of age, was diagnosed with lung adenocarcinoma stage iii and. Tarceva dosage: Oral. During the same period patient was treated with AVASTIN ((5 Mg/kg, Q2w)) (View Avastin Review and Avastin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ).

6844252-7 | Cardiopulmonary Failure, Lung Neoplasm Malignant, Malignant Neoplasm Progression
Adverse event was reported on Jun 25, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with lung neoplasm malignant and. Location: COLOMBIA , 65 years of age, Patient had the following side effects: cardiopulmonary failure, lung neoplasm malignant, malignant neoplasm progression.

6839936-0 | Asthenia, Fluid Retention
on Jun 24, 2010 Male patient from UNITED STATES , 63 years of age, was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: asthenia, fluid retention. Tarceva dosage: (100 Mg, Qd), Oral. Patient was hospitalized.

6839929-3 | Pulmonary Embolism
on Jun 24, 2010 Male patient from UNITED STATES , 79 years of age, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6839705-1 | Cholangitis, Decreased Appetite, Interstitial Lung Disease
Patient was taking Tarceva (View Usage). Patient had the following side effects: cholangitis, decreased appetite, interstitial lung disease on Jun 23, 2010 from JAPAN Additional patient health information: Female patient , 76 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), COLDRIN (CLOFEDANOL HYDROCHLORIDE) (View Coldrin (clofedanol Hydrochloride) Review and Coldrin (clofedanol Hydrochloride) Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ).

6839703-8 | Asthenia, Cardiopulmonary Failure, Rash Pustular
Adverse event was reported on Jun 23, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: Oral) . Location: POLAND , 67 years of age, After Tarceva was administered, patient had the following side effects: asthenia, cardiopulmonary failure, rash pustular.

6839660-4 | Circulatory Collapse, Ileus Paralytic, Leukocytosis, Necrotising Colitis, Peritonitis, Sepsis, Septic Shock
on Jun 23, 2010 Female patient from GERMANY , 71 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: circulatory collapse, ileus paralytic, leukocytosis, necrotising colitis, peritonitis, sepsis (What is sepsis?), septic shock. Tarceva dosage: Oral. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ).

6836622-8 | Swelling Face, Urticaria
on Jun 23, 2010 Female patient from UNITED STATES , 72 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: swelling face, urticaria. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6832318-7 | Pulmonary Embolism
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?) on Jun 22, 2010 from JAPAN Additional patient health information: Male patient , 75 years of age, . Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with TS 1 (Oral) (View Ts-1 Review and Ts-1 Label ).

6832307-2 | Anuria, Blood Pressure Immeasurable, Diarrhoea
Adverse event was reported on Jun 22, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: 150 Mg, Qd, Oral) was diagnosed with non-small cell lung cancer and. Location: BELGIUM , 64 years of age, Patient experienced the following unwanted or unexpected effects: anuria, blood pressure immeasurable, diarrhoea. During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ).

6831684-6 | Malignant Neoplasm Progression, Prostate Cancer
on Jun 22, 2010 Male patient from UNITED STATES , 81 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: malignant neoplasm progression, prostate cancer (What is prostate cancer?). Tarceva dosage: 150 Mg, Od, Oral.

6829137-4 | Fall, Femoral Neck Fracture
on Jun 21, 2010 Male patient from CHINA , 69 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: fall (What is fall?), femoral neck fracture. Tarceva dosage: 150 Mg, Oral. Patient was hospitalized.

6821725-4 | Haemoptysis
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: haemoptysis on Jun 17, 2010 from COLOMBIA Additional patient health information: Male patient , 63 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), MORPHINE (View Morphine Review and Morphine Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6819561-8 | Basophil Count Decreased, Eosinophil Count Decreased, Haematocrit Decreased, Haemoglobin Decreased, Hepatic Mass, Lymphadenopathy, Lymphocyte Count Decreased, Malignant Neoplasm Progression, Pain
Adverse event was reported on May 31, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: Oral) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 61 years of age, Patient had the following side effects: basophil count decreased, eosinophil count decreased, haematocrit decreased, haemoglobin decreased, hepatic mass, lymphadenopathy, lymphocyte count decreased, malignant neoplasm progression, pain (What is pain?). During the same period patient was treated with GEMZAR (View Gemzar Review and Gemzar Label ), ELOXATIN (View Eloxatin Review and Eloxatin Label ).

6819250-X | Bile Duct Cancer, Deep Vein Thrombosis, Depression, Hypercalcaemia, Metastatic Neoplasm, Nausea, Osteoporosis, Pain
on Jun 16, 2010 Female patient from UNITED STATES , 58 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: bile duct cancer, deep vein thrombosis (What is deep vein thrombosis?), depression (What is depression?), hypercalcaemia, metastatic neoplasm, nausea (What is nausea?), osteoporosis (What is osteoporosis?), pain (What is pain?). Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with COLACE (DOCUSATE SODIUM) (View Colace (docusate Sodium) Review and Colace (docusate Sodium) Label ), SENOKOT (View Senokot Review and Senokot Label ), AMITRIPTYLINE HYDROCHLORIDE (View Amitriptyline Hydrochloride Review and Amitriptyline Hydrochloride Label ), ZOFRAN (View Zofran Review and Zofran Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6818826-3 | Cardiopulmonary Failure, Disease Progression, Lung Neoplasm Malignant
on Jun 15, 2010 Male patient from COLOMBIA , 66 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: cardiopulmonary failure, disease progression, lung neoplasm malignant. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6818531-3 | Haemoptysis
Patient was taking Tarceva (View Usage). Patient had the following side effects: haemoptysis on Jun 16, 2010 from COLOMBIA Additional patient health information: Male patient , 65 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: (150 Mg,qd), Oral. During the same period patient was treated with BISACODYL (BISACODYL) (View Bisacodyl (bisacodyl) Review and Bisacodyl (bisacodyl) Label ), MORPHINE (View Morphine Review and Morphine Label ).

6814906-7 | Nephrolithiasis
Adverse event was reported on Jun 14, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 72 years of age, After Tarceva was administered, patient had the following side effects: nephrolithiasis. Patient was hospitalized.

6812102-0 | Fall, Hypotonia, Shock
on Jun 12, 2010 Male patient from ITALY , 78 years of age, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: fall (What is fall?), hypotonia, shock. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6812093-2 | Cardiac Failure, Malignant Neoplasm Progression, Non-small Cell Lung Cancer
on Jun 11, 2010 Female patient from UNITED KINGDOM , 71 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient had the following side effects: cardiac failure, malignant neoplasm progression, non-small cell lung cancer. Tarceva dosage: (150 Mg,qd), Oral. During the same period patient was treated with PEMETREXED (View Pemetrexed Review and Pemetrexed Label ), VITAMIN B12 (View Vitamin B12 Review and Vitamin B12 Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6811808-7 | Decubitus Ulcer, Interstitial Lung Disease, Pleural Effusion
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: decubitus ulcer, interstitial lung disease, pleural effusion on Jun 14, 2010 from JAPAN Additional patient health information: Female patient , 49 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: 100 Mg, Qd, Oral. During the same period patient was treated with TEGRETOL (View Tegretol Review and Tegretol Label ), MUCOSOL (ACETYLCYSTEINE (View Mucosol (acetylcysteine Review and Mucosol (acetylcysteine Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ). Patient was hospitalized.

6807485-1 |
Adverse event was reported on Jun 10, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: Oral) . Location: UNITED STATES , 64 years of age, .

6801012-0 | Ocular Icterus, Seborrhoeic Dermatitis, Vision Blurred, Vomiting
on Jun 09, 2010 Male patient from CANADA , 61 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: ocular icterus, seborrhoeic dermatitis, vision blurred, vomiting. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), MORPHINE (View Morphine Review and Morphine Label ). Patient was hospitalized.

6798241-1 | Haemoptysis, Rash
on Jun 08, 2010 Female patient from , 48 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: haemoptysis, rash (What is rash?). Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6797340-8 | Dehydration, Diarrhoea, Dysphagia, Fall, Hip Fracture, Nausea, Rash Erythematous
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, diarrhoea, dysphagia, fall (What is fall?), hip fracture, nausea (What is nausea?), rash erythematous on Jun 08, 2010 from UNITED STATES Additional patient health information: Male patient , 61 years of age, was diagnosed with non-small cell lung cancer metastatic and. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6796335-8 | Anaemia, Haematoma, Thrombocytopenia
Adverse event was reported on Jun 07, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg), Oral) was diagnosed with non-small cell lung cancer and. Location: PORTUGAL , 74 years of age, weighting 149.9 lb, Patient had the following side effects: anaemia, haematoma, thrombocytopenia. During the same period patient was treated with NOLOTIL (View Nolotil Review and Nolotil Label ), DEFLAZACORT (DEFLAZACORT) (View Deflazacort (deflazacort) Review and Deflazacort (deflazacort) Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), STRESSTABS (STRESSTABS) (View Stresstabs (stresstabs) Review and Stresstabs (stresstabs) Label ). Patient was hospitalized.

6788235-4 | Cerebral Haemorrhage, Thrombocytopenia
on Jun 04, 2010 Male patient from UNITED STATES , 57 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: cerebral haemorrhage, thrombocytopenia. Tarceva dosage: 150 Mg, Qd, Oral.

6788208-1 | Cerebrovascular Accident, Psychotic Disorder, Stomatitis, Thrombosis
on Jun 04, 2010 Female patient from UNITED STATES , 71 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident, psychotic disorder (What is psychotic disorder?), stomatitis, thrombosis. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6787262-0 | Anaemia, Asthenia, Cough, Decreased Appetite, Dermatitis Acneiform
Patient was taking Tarceva (View Usage). Patient had the following side effects: anaemia, asthenia, cough, decreased appetite, dermatitis acneiform on Jun 05, 2010 from PHILIPPINES Additional patient health information: Male patient , 56 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with MULTI VITAMIN (View Multi-vitamin Review and Multi-vitamin Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), DOMPERIDONE (DOMPERIDONE) (View Domperidone (domperidone) Review and Domperidone (domperidone) Label ), LEVODROPROPIZINE (LEVODROPROPIZINE) (View Levodropropizine (levodropropizine) Review and Levodropropizine (levodropropizine) Label ), SALBUTAMOL (SALBUTAMOL) (View Salbutamol (salbutamol) Review and Salbutamol (salbutamol) Label ). Patient was hospitalized.